Biological drugs in patients with psoriasis: a drug-utilization study using Tuscan administrative data banks

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (L04AB04) adalimumab

  adalimumab

  (L04AB01) etanercept

  etanercept

  (L04AB02) infliximab

  infliximab

  (L04AC10) secukinumab

  secukinumab

  (L04AC05) ustekinumab

  ustekinumab
• Medical condition to be studied:
  Psoriasis

Population studied

• Age groups:
  Preterm newborn infants (0 – 27 days)

  Term newborn infants (0 – 27 days)

  Infants and toddlers (28 days – 23 months)

  Children (2 to < 12 years)

  Adolescents (12 to < 18 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  2000

Study design details

• Main study objective:
  To evaluate the utilization of biologic drugs for psoriasis in the population of Tuscany using real-world data
• Outcomes:
  - Identification of longitudinal patterns of adherence behavior through trajectory models - Investigation of switches of PSObio drugs
• Data analysis plan:
  Treatment trajectories will be identified through two different methodological approaches: the first one is purely descriptive and it is based on the cluster analysis, whereas the second one is the group-based trajectory modeling (GBTM). Furthermore, patterns of switches will be identified using the state sequence analysis.